• Tingo Mobile Plc, subsidiary of leading African agri-fintech, joins forces with Visa to enhance financial services offering and drive greater adoption on its platforms
• Two companies share vision of bringing empowerment through access to financial services; financial inclusion is key to reducing poverty
• Visa is expected to help enhance Tingo’s presence in Nigeria and drive expansion across the African continent and beyond

The leading agri-fintech in Africa, Tingo (OTCQB: IWBB) partners with Visa Inc., in an effort to augment its offerings across Nigerian financial services and expand its market reach across Africa—the second-largest continent by population (https://ibn.fm/exiGe). With its unique rural community’s focus, Tingo’s vision is to deliver a powerful social impact through financial inclusion while becoming Africa’s leading agri-fintech business. The company remains to transforming rural farming communities—one of the most underserved segments of the market—by connecting them through its proprietary platform, thus helping them generate sustainable income. Growing the agricultural sector in Africa is key to reducing poverty and delivering a transformational impact through greater opportunities. The agriculture sector generates around 30–40% of gross domestic product and employs 65–70% of the total labor force in Africa (https://ibn.fm/R2bMY). Financial inclusion, one of the core Sustainable Development Goals, also helps eradicate poverty. Access to financial services simplifies day-to-day living and allows businesses and families to make long-term plans and cover unexpected emergencies. The problem of financial inclusion—or the lack of it—is especially acute in Africa, as almost half of the population does not have access to formal financial services. For example, in 2020, around 56% of Nigerian adults didn’t have access to traditional financial services (https://ibn.fm/O7VOn). To expand its market footprint across Africa and continue developing the business in Nigeria, Tingo partnered with the world’s heavyweight in the payment space, Visa. The partnership is intended to enhance the offering of financial services on Tingo’s platforms and drive their greater adoption, especially digital payments. With a shared vision to enable individuals, businesses, and economies to thrive through financial services, Visa is expected to be a powerful lever to drive Tingo’s expansion across the African continent and beyond. “With this agreement, Tingo Mobile will be able to issue Visa cards (both physical and virtual) to users on Nwassa and Tingo Pay.” Nwassa is Tingo’s digital marketplace platform connecting African farmers with other players in the agricultural value chain and Tingo Pay is the company’s proprietary payment platform available to the public. But the partnership will not stop there. Committed to financial education, Tingo aims to increase financial literacy and greater economic independence across the continent, for which alliance with Visa will be crucial. Tingo and Visa will join forces to deliver knowledge and learning tools to empower communities with adequate information so that they can fully leverage the benefits of increased access to financial services. Visa appears equally optimistic about the upcoming collaboration as this global payment’s leader views partnerships with companies such as Tingo as essential to its business model. “Whether it is changing the way people invest, manage money, receive loans or send real-time payments to friends and family, Visa is a natural partner for fintech companies, providing them with new ways to reach their customers through Visa’s vast network and global scale.”, said Otto Williams, Senior Vice President, Head of Products and Solutions for Visa Central and Eastern Europe, Middle East and Africa. Tingo remains committed to innovation and expansion of services across the continent. What started as a vision to build an ecosystem that supports the largely unbanked agricultural sector in Nigeria 20 years ago now is a business with $600 million in annual revenues and almost 10 million users (https://ibn.fm/bK4WG). The company appears confident that the growth will continue. For more information, visit the company’s website at www.TingoGroup.com. NOTE TO INVESTORS: The latest news and updates relating to IWBB are available in the company’s newsroom at https://ibn.fm/IWBB

• German Social Democrat-led coalition expected to liberalize medical cannabis market
• Analysts predict over one million medical cannabis patients in Germany by 2024, market estimated to reach $8.9 billion by 2028
• RYAH entered German market via observational study with Four 20 Pharma GmbH
• RYAH provides IoT product ecosystem of volume-control devices, medicine-carrying components, mobile applications
• RYAH ecosystem offers reliable way for researchers and clinicians to develop well-controlled research environments

Germany’s recent 2021 election is expected to result in a new political environment via a coalition containing cannabis-positive political factions that aim to liberalize the country’s plant-based medicine market (https://ibn.fm/t1Zgg). RYAH Group (CSE: RYAH), the leader in volume-control technology for plant-based medicine, is already on track to penetrate the German market with a strategic partnership aiming to catalyze the company’s mission of providing remote-health solutions and analytics-based patient treatments to the world. Germany’s winning party – the Social Democrats – are currently in talks with the Greens and Free Democratic Party to form a coalition to replace Angela Merkel’s current government. A pre-election analysis by Volt Face revealed that the Social Democrats “can generally be considered pro-cannabis policy reform,” with even greater pro-cannabis sentiment among the other members of the proposed coalition (https://ibn.fm/PpZMv). Though access to cannabis in Germany may be limited, the current system appears to be serving as a model for the rest of the European Union through policies that demonstrate a controlled, prescribed, and relatively efficient medical cannabis market (https://ibn.fm/kGG8F). Recent reports by the Prohibition Partners organization, based on translated publications from the German Bundestag, provided positive insights into the German medical cannabis model and possible implications for the rest of the European Union. According to the report, there are slightly more than 13,000 complete patient records from roughly 128,000 patients receiving medical cannabis in the country. Market analysts predict one million medical cannabis patients in Germany by 2024 with a total market value of $8.9 billion by 2028, making it one of “the world’s most valuable medical cannabis markets,” according to the New Frontier Data organization. “Germany represents one of the most important and influential plant-based medicine markets in Europe, and we are thrilled to be initiating a pilot program with Four 20 Pharma GmbH in the region,” said Gregory Wagner, RYAH Group CEO. “Four 20 has a strong network of doctors and patient care facilities, making it an excellent partner to pilot RYAH’s smart inhaler and proprietary data analytics as the industry moves towards perfecting prescribing practices and patient regimens.” RYAH provides an ecosystem of IoT products that include volume-control devices, medicine-carrying components, and mobile applications. Used together, they can provide a reliable way for researchers and clinicians to develop well-controlled environments to study the use of cannabis for chronic medical conditions and palliative care. Along with treatment administration, RYAH’s infrastructure aims to generate AI-powered models that can provide precision treatments for various diseases. RYAH is dedicated to leveraging technological innovation that unlocks the power of data to provide better patient outcomes. The company’s robust intellectual property portfolio, comprised of AI-powered technology and portable, cost-effective products, is positioning the company to capture and capitalize on growth opportunities in Germany, the European Union, and beyond. For more information, visit the company’s website at www.RYAHGroup.com. NOTE TO INVESTORS: The latest news and updates relating to RYAH are available in the company’s newsroom at https://ibn.fm/RYAH

• INND appears committed to creating a leadership dream team announcing Adnan Shennib as the Company’s CTO and president of international operations
• Shennib is a proven leader and entrepreneur in hearing medical devices; he developed several commercially successful hearing innovations
• INND is poised to leverage Shennib’s invaluable insight and expertise to develop new disruptive products and expand Company’s partnerships around the world

InnerScope Hearing Technologies (OTC: INND) has announced that Adnan Shennib, a seasoned industry professional, will join as chief technology officer (“CTO”) and the president of international operations responsible for expanding the Company’s partnerships with manufacturers, distributors, and innovators worldwide. As an industry veteran with over 30 years of experience in hearing innovations, Shennib brings unmatched technology and business competence to solidify InnerScope’s leadership position in the hearing aid market (https://ibn.fm/90eGC). Shennib’s unique background includes leading positions with notable hearing aid manufacturers. One of them is ReSound(R), an industry champion that developed the world’s first remotely controlled hearing aid product. But Shennib is much more than an executive with significant experience in the hearing aids sector. Over the years, he became a well-known Silicon Valley medical device entrepreneur with several commercially successful hearing innovations under his belt. He is also a praised innovator who developed novel hearing solutions that went on to receive the Medical Device Excellence Award and become featured by major media outlets, including CNN, The New York Times, The Dr. Oz Show, USA Today, and Inc. Magazine. He also founded InSound Medical, a company that invented the Lyric(R) hearing device, the first invisible, extended-wear hearing aid, which Sonova-Phonak(R) acquired in 2010 in a deal valued at $169 million. His entrepreneurial endeavors also include iHEAR Medical Inc., a company with a demonstrated track record in bringing novel hearing solutions to the market. There he led the development of several revolutionary innovations, including a groundbreaking online platform for the direct-to-consumer hearing market and, and iHEARtest(TM), the only FDA-cleared home hearing test. Shennib joins the Company through iHEAR Medical Inc. as InnerScope recently acquired the latter. InnerScope is optimistic that the addition of Shennib to the leadership team will help the Company develop new and improved products that can successfully challenge conventional hearing aids. “We are proud to add Mr. Shennib to our team of seasoned experts as InnerScope’s CTO. Mr. Shennib is a pioneer in the hearing industry with a proven track record of developing patentable, groundbreaking discoveries in hearing technology. With our recent acquisition of iHEAR, we are especially excited for Mr. Shennib to lead InnerScope’s new research and development team at our new FDA-registered manufacturing facility in San Leandro, California.” stated Matthew Moore, president and CEO of InnerScope. Shennib appears equally enthusiastic about the new role. “I am excited to join the InnerScope team to advance its mission of providing affordable advanced hearing solutions,” he said, concluding that the initial focus will be on developing products based on new understandings of consumer trends and behavior. InnerScope launched its hearing aids on FSAstore.com, HSAstore.com, and WellDeservedHealth.com to consumers enrolled in flexible spending accounts (“FSA”), health saving accounts (“HSA”), and employers’ health incentive programs. For more information, visit the company’s website at www.INND.com and the company’s e-commerce website: www.MyHearIQ.com. NOTE TO INVESTORS: The latest news and updates relating to INND are available in the company’s newsroom at https://ibn.fm/INND

• September 2021 saw four new additions to FuelPositive’s management team
• Each of the new appointments brings with them decades of experience, technical know-how and strategic approaches that will guide the company’s future decisions and investments
• Ian Clifford, FuelPositive’s CEO and chair, has acknowledged that some of these appointments have come at “just the right time”

Ian Clifford, the chief executive officer and chair of the board at FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF), while appearing in an interview on the company’s YouTube channel, expressed his optimism and enthusiasm about four new appointments the company made over the month of September. “It’s just a great day for us to add to our already stellar team four new faces with such a broad range of skills and backgrounds. All of these people are key team players for us, so we’re really pleased with this announcement,” he noted (https://ibn.fm/c2Zi9). Clifford acknowledged the value that the four will be bringing to the table, ranging from decades of experience to an intimate understanding of how the industry works. This is particularly useful since the company is no longer solely an R&D company, but rather an enterprise that is working towards ensuring the excellence of its work as it commercializes its lead technology — modular and scalable carbon-free ammonia (“NH3”) (https://ibn.fm/HTKGe). In the interview, Clifford pointed out Olushola (Shola) Ashiru’s long-term support of FuelPositive. He noted the tremendous value she will bring, owing to her understanding of the United States capital markets, ultimately offering perspective into the company’s future environmental investments. This, he acknowledged, complements Nelson Leite’s decades of experience in sophisticated mass production, sales, marketing and engineering as he assumes the new role of chief operating officer (“COO”) of the company. Nelson will play an integral role in building FuelPositive’s phase 2 demonstration systems scheduled for delivery throughout 2022. “Also, as we build those phase 2 systems, we’re going to be looking at mass production manufacturing and what we need to do in order to set that up. Nelson has systems that he’s developed and built with the likes of Toyota, Tesla and other extremely sophisticated manufacturers, so he’ll be a tremendous addition to the team,” Clifford reckoned (https://ibn.fm/c2Zi9). Just like Shola, Francois Desloges, who joins FuelPositive’s executive leadership, has been involved in the company in different capacities over the years. Clifford recognized his skill as a research analyst and scientist, noting that he will be vital in advancing a lot of the various subtle technologies that will be spinning out of the company’s core carbon-free ammonia technology. Lastly, Clifford highlighted Jennifer Spencer’s appointment into the company’s executive leadership team. With her decades of experience in public relations, Clifford believes that she will be able to craft messages that multiple audiences worldwide can understand. Her appointment is founded on the importance of explaining and educating the public about the impact of FuelPositive’s technology, thereby demystifying any myths surrounding it and bringing it closer to the people. Jennifer will also work closely with the company’s consultants and strategic suppliers, ensuring that the message is consistent across all the different audiences. “(Jennifer is) Another great addition to the team at just the right time as the message is getting out,” Clifford noted (https://ibn.fm/c2Zi9). These new appointments are in line with FuelPositive’s ambitious move towards growing its market share and diversifying its revenue streams from a solely R&D company. The additions will help steer the company in the right direction, even as it works towards achieving both the short-term and long-term goals it has set so far. You can watch the whole interview with Ian Clifford here https://ibn.fm/c2Zi9. For more information, visit the company’s website at www.FuelPositive.com. NOTE TO INVESTORS: The latest news and updates relating to NHHHF are available in the company’s newsroom at https://ibn.fm/NHHHF

• Mydecine just announced the successful synthesis of a novel psilocin analogue, a tryptamine
• The achievement adds to the company’s library of patent-pending tryptamines for medical use and therapy, and is seen as verifying the value of Mydecine’s AI-driven drug discovery program
• Mydecine has also confirmed its participation in the Wonderland: Miami psychedelic medicine event scheduled for November 8-9, 2021, where the company will share its recent research advancements and goals going forward

Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) just announced the successful synthesis of a novel psilocin analogue, a tryptamine, that has proven to have improved pharmaceutical properties (https://ibn.fm/I2lX7). The success of this study adds to Mydecine’s library of patent-pending tryptamines while also building upon the company’s strategy to enhance the safety and efficacy of its drug development candidates for both medical use and therapy. Mydecine has been a biotechnology and digital tech pioneer, pushing boundaries with its AI-driven drug discovery program. The integration of AI technology, which is currently done in partnership with Applied Pharmaceutical Innovation (“API”) at the University of Alberta, has accelerated the company’s natural product research and novel drug design. This move has also allowed it to scale much faster than would have been possible had Mydecine opted for traditional research methods. Dr. Khaled Barakat, the Principal Investigator at API and University of Alberta Associate Professor, noted, “Our AI technologies construct billions of new drug candidates and filter them for their ability to modulate the activity of the psychedelic-related targets. These AI models also predict the interactions and affinity of each drug candidate to the level of a single atom.” “By considering the unique structural and dynamical fingerprint of each target, our AI-drug discovery program paves the road towards designing selective modulators, hence, reducing any potential side effects that may emerge in the future,” he added. Mydecine’s addition of this compound has demonstrated the company’s ability to achieve proven principles of drug chemistry, time course of action, improved delivery, and compound stability. More importantly, the technology has helped with the effective production of an extensive base of preclinical, in vitro data which is integral to the company’s expansion of its drug pipeline. While making the announcement, Rob Roscow, Mydecine’s Chief Scientific Officer (“CSO”), noted, “Our ability to rapidly uncover safer and more efficacious novel compounds, such as this psilocin analogue, is a true testament to the value and success of our AI-driven drug discovery program. As we progress forward, we see great value from this development as we can now leverage the achieved receptor binding data for serotonin receptor (5-HT2A) and expand our drug pipeline focusing on the agonistic activity of psilocin and other tryptamines at different ratios on serotonin receptors.” Since it was founded in 2020, Mydecine has operated on the guiding principle that there is a significant unmet need and lack of innovations within the therapeutic and mental health environments. Through technology, the company hopes to remedy this situation. This recent milestone demonstrates what the company can do and the fact that there are potential psychedelic-based solutions for mental health and addiction. Mydecine will share this and other achievements at this year’s Wonderland Miami event, scheduled for November 8-9, an event dubbed as the largest psychedelic medicine business event ever put together (https://ibn.fm/b1YEZ). The event will be held at the Adrienne Arsht Center for the Performing Arts in Miami, Florida, and Mydecine expects to share its technological advancements, recent discoveries, and goals. For more information about the event, please visit the event’s website at www.microdose.buzz/wonderland/miami For more information, visit the company’s website at www.Mydecine.com. NOTE TO INVESTORS: The latest news and updates relating to MYCOF are available in the company’s newsroom at https://ibn.fm/MYCOF

• American Gaming Association’s Gaming CEO Outlook expects industry growth in 2020 driven by new hiring, wage growth, and capital investment
• PLGNF sees explosive growth in October 2021 with a 1500% betting handle increase, and betting turnover reached approximately $1.6 million per day from $53,500 for September
• PLGNF’s IP-protected iGaming software solutions include Live Dealer Casino, E-Table Games, Daily Fantasy Sports
• PLGNF applications run securely on any browser without app store download, do not require sharing sensitive data

Playgon Games (TSX.V: DEAL) (OTCQB: PLGNF), a SaaS technology company focused on developing and licensing digital content for the growing global iGaming market, is experiencing exponential growth with a 1500% betting handle increase in October (https://ibn.fm/zADPz), well ahead of optimistic predictions published by the American Gaming Association (“AGA”) in a recent report (https://ibn.fm/Kb7Ns). “We are a more resilient industry because of the COVID-19 pandemic,” said Aristocrat Technologies CEO and AGA Chairman Trevor Croker. “As the gaming industry looks to 2022 and beyond, our impressive recovery will continue to create jobs, support communities, and generate needed taxes.” The AGA is the premier national trade group representing the $261 billion U.S. casino industry, supporting 1.8 million jobs across the United States. The group’s newly published Gaming CEO Outlook suggests bullish industry confidence across the industry, with nearly half of AGA-member CEOs expecting improved 2022 business conditions, driven by expected increases in new hiring (71%), wage growth (63%), and capital investment (39%). “AGA’s inaugural Gaming CEO Outlook reflects the strength of our recovery and consumer demand for our world-class entertainment offerings,” said Bill Miller, AGA president and CEO. “The promising outlook is built on our innovation.” PLGNF leads this innovative change with its multi-tenant gateway that enables online operators to offer users iGaming software solutions, including Live Dealer Casino, E-Table Games, and Daily Fantasy Sports. With privacy in focus, PLGNF’s technology allows customers to access the platform without sharing sensitive data while offering seamless integration at the operator level. Fast and secure, PLGNF’s games run fast on all browsers and devices like any native application without requiring an app store download. “We knew our proprietary technology was innovative, however the reception we have received from our partners and clients has been unparalleled,” said Darcy Krogh, CEO of Playgon Games. “This is noticeable from the player wagering activity, which has increased to 305,000 bets for the half-month of October compared to 132,000 bets for the entire month of September. We are witnessing at least 100% growth across all of our key indicators. PLGNF’s management team brings over three decades of iGaming experience to the industry, with multiple successful exits. With a focus on delivering a first-class gaming experience to this generation of mobile-first gaming enthusiasts, PLGNF is positioned to lead the hyper-growth iGaming market due to high entry barriers and a valuable portfolio of IP-protected assets. For more information, visit the company’s website at www.Playgon.com. NOTE TO INVESTORS: The latest news and updates relating to PLGNF are available in the company’s newsroom at https://ibn.fm/PLGNF

• Tryp just filed an IND with the FDA for its TRP-8802 clinical candidate for its Phase 2a clinical trial
• The trial is set to commence in 2022, subject to a favorable review by the FDA
• The study will be conducted in collaboration with the University of Michigan and will aim at evaluating the safety and clinical utility of psilocybin for fibromyalgia

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) just announced its submission of an Investigational New Drug (“IND”) application to the United States Food and Drug Administration (“FDA”) for its TRP-88802 clinical candidate. This application follows the commencement of Tryp’s Phase 2a clinical trial that explores psilocybin-assisted therapy’s safety and preliminary effectiveness among individuals dealing with fibromyalgia. While making the announcement, Greg McKee, the Chairman and Chief Executive Officer of Tryp, noted, “We have been working diligently to complete this IND submission and are eager to initiate what will be one of the first evaluations of psilocybin to treat fibromyalgia in a Phase 2 study,” (https://ibn.fm/KVqCt). This trial is being conducted in collaboration with the University of Michigan, spearheaded by Kevin Boehnke, Ph.D. from the university. It will involve 20 fibromyalgia patients and include various exploratory endpoints, particularly given the high prevalence of co-morbidities that include, but are not limited to anxiety, depression, and poor sleep quality. Since its inception, Tryp has aimed to lead the next wave of psychedelic drug development, pushing beyond mental health. Its focus on psilocybin-based treatments for chronic pain and other indications has proven useful and highly effective. With this specific study, the company seeks to offer a more effective fibromyalgia solution than those that are currently available in the market today. It also aims to provide a long lasting solution with fewer side effects, ultimately affording patients better treatment for their condition. “Many fibromyalgia patients find insufficient relief from the currently available, FDA-approved treatments for the disease due to their limited efficacy and significant side effects. We have an opportunity with Tryp to conduct a Phase 2a study that evaluates the safety and clinical utility of psilocybin for fibromyalgia as we target the origins of the disease rather than simply treating patient symptoms,” noted Dr. Boehnke. Research has shown that the administration of psilocybin increases neuroplasticity while also addressing disrupted neural connections that are typically associated with fibromyalgia and other nociplastic pain indications. This Phase 2a study will seek to capitalize on that, starting with the administration of TRP-8802, coupled with psychotherapy. The study is expected to commence in 2022, subject to a favorable review of the IND by the FDA. “Through our close collaboration with Dr. Boehnke and other experts in the space, we have an appreciation of the limitations of current treatments for this disease and a determination to develop a more effective therapy for the millions of patients suffering from fibromyalgia,” noted Mr. McKee. For more information, visit the company’s website at www.TrypTherapeutics.com. NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

• The distribution component unlocks a new revenue source for the company, helping drive future growth
• MINDCURE’s platform was built as a digital tool and distribution platform, and has already been used for deployment and distribution of ketamine for depression and pain
• Digital therapeutics market is projected to reach USD $13.1 billion by 2026 from USD $3.4 billion in 2021 at a CAGR of 31.4 %, a substantial increase primarily driven by the COVID-19 pandemic and the stressors associated with it
• MINDCURE’s target areas and value proposition list numerous benefits for therapists, patients, payers, and drug and protocol developers, through the proprietary technology and platform.

A recent non-binding Letter of Intent (“LOI”) was signed between Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH), a leader in advanced proprietary technology and research for psychedelics, and Awakn Life Sciences (NEO: AWKN) (OTCQB: AWKNF), a biotech company with clinical operations researching, developing, and delivering psychedelic medicine to treat addiction. Under the LOI, MINDCURE becomes a distributor of Awakn’s ketamine-assisted psychotherapy for Alcohol Use Disorder in the United States and Canada, through its proprietary digital therapeutics platform, iSTRYM. This is MINDCURE’s first international partnership with industry leaders developing rigorous psychedelics protocols and drugs that can be distributed through the company’s platform to support both therapists and patients. As well as distributing its partners’ protocols, the company will also be distributing its own protocols through iSTRYM. With the minimum viable product (“MVP”) version of iSTRYM already released into partner clinics across North America, the company expects to partner with 75 clinics in both Canada and the U.S. when beginning full commercia deployment in early 2022, and to double that number by Q4 2022. The distribution component of iSTRYM opens up a new source of revenue for the company, which will help fuel further growth and expansion strategies. MINDCURE’s digital therapeutics (“DTx”) platform was built to be scaled at a global level as a drug-agnostic digital tool and distribution platform. The company’s own protocols of ketamine for depression and ketamine for pain have already been created, with ketamine for an undisclosed indication currently in development. With additional revenue to drive growth goals, the company expects to be able to leverage multiple emerging opportunities on the fast-growing digital therapeutics market. Globally, the digital therapeutics market is projected to reach USD $13.1 billion by 2026 from USD $3.4 billion in 2021, at a CAGR of 31.4% (https://ibn.fm/ARbYX). DTx is a subdivision of digital health, but not all digital health solutions are DTx. According to the Digital Therapeutics Alliance, DTx deliver evidence-based therapeutic interventions that are driven by high quality software programs to prevent, manage, or treat a medical disorder or disease. They are used independently or in concert with medications, devices, or other therapies, to optimize patient care and health outcomes. The rise in DTx can be attributed to the mass use of smart devices by consumers. Another element that has driven the demand for digital therapies has been the COVID-19 pandemic, with its associated stressors and increase in mental health conditions. A variety of segments stand to benefit from DTx and MINDCURE’s proprietary platform – therapists, patients, payers, and drug and protocol developers. Each segment has its own value proposition, according to the company:

• Therapist Value Proposition:

• Cost reduction
• More favorable outcomes
• An increased portfolio of protocols that can expand guidance on practice and payer code guidance
• Patient Value Proposition
  • Improved compliance
  • Outcomes are optimized
  • Proofing of the safety and efficacy
• Payer Value Proposition
  • Access to cumulative data on the patient outcomes and compliance
• Drug and Protocol Developer Value Proposition
  • A partner for distribution and sales
  • Provide line-of-sight to compliance; de-risk new protocol deployment

For more information, visit the company’s website at www.MindCure.com. NOTE TO INVESTORS: The latest news and updates relating to MCURF are available in the company’s newsroom at http://ibn.fm/MCURF

• The case study based on ShamirMuzik and his journey will serve as a means of showing how Fan Pass can help increase artist reach, revenue, and visibility
• The platform’s November contest can earn artists up to $175 ($150 for streaming + $25 for Instagram promotion) by performing live five times during the month
• Fan Pass has released its first fall merchandise line, with a limited time offering consisting of ten new designs donning over 20 new color choices

Mobile technology and marketing company Friendable (OTC: FDBL) announced the addition of ShamirMuzik to the company’s Fan Pass Live Streaming artist platform (https://ibn.fm/y6S4p). An affiliate of Warner Bros. Entertainment and currently part of independent label ‘The MHZ,’ ShamirMuzik brings along his existing fan base, social media followers, streams and an existing, robust connection with his audience. The artist has already achieved over 1 million streams each on YouTube and Spotify, with features on Netflix, VH1, Power 105.1, MTV and more. “I am very excited to embark on my journey with Fan Pass. They are a great platform for artists to utilize, especially when it comes to connecting with your fan base and supporters,” ShamirMuzik said. “I’m encouraging artists to jump on board because this is the future of a new wave that nobody has seen yet.” The company is working on a case study that revolves around every step of ShamirMuzik’s journey with the platform, showing examples of how artists can utilize the Pro Services offering to enhance the livestream experience with their own custom merchandise, eCommerce store, ticket sales, and more. The case study on ShamirMuzik will run through the end of the year and will serve as a way for Friendable to share the artist journey and how Fan Pass can help to extend reach, revenue, and visibility. ShamirMuzik currently has:

• Spotify – 1 million+ streams
• YouTube – 1 million+ streams
• Instagram – 114,000+ followers
• YouTube – 4,800+ followers and 1.4 million+ video views
• Twitter – 1,200+ followers

“Artists telling other artists about their experience, sharing with fans and allowing our team to share a case study that maps the next 60 days of Shamir’s journey with our platform, company and team is huge,” Friendable CEO Robert A. Rositano Jr. said. “We believe this is an important step as we seek expansion of our platform, services and artist database in the coming months as well.” Fan Pass offers Pro Services to artists and musicians who want to build a brand, attract more fans, and earn more income as a musician with quality logo graphics and merchandise designs. Pro Services come in three categories – Artist/Band Logo Design, Merch Designs, and Marketing Materials. Each of these categories is broken down into three tiers of pricing/product availability.

• Artist/Band Logo Design

• Basic – $50 – A single high-resolution design placed on one item
• Standard – $75 – Three high-resolution designs placed on three items
• Custom (25% off) – $110 – Five high-resolution designs placed on three items
• Merch Designs
  • Basic – $100 – Single high-resolution design (on a t-shirt in your store)
  • Standard – $275 – Three high-resolution designs (two t-shirts, one hoodie)
  • Pro (25% off) – $500 – Five high-resolution designs (placed on any five merch items available)
• Marketing Materials
  • Basic – $45 – Social Ad/Announcement designs to promote the next three events
  • Standard – $65 – Social Ad/Announcement designs to promote next five events
  • Premium (25% off) – $100 – The Standard Package, plus two merch ad designs to market the collection on social media

To begin the process, artists fill out the online form that gathers information about themselves or their musical group, including colors and styles they like. Next, Fan Pass designers create image designs for approval or revision requests. Once approved, the final graphics files are sent to the artist. Meanwhile, the company announced plans to increase the number of live performances given by the artists on the Fan Pass platform through a unique promotion that has been posted on the company’s Instagram page (https://ibn.fm/Npfl9). The headline is “Go Live, Earn $150!” Artists on the platform who go live in November can earn cash prizes every time they put on live performances (up to $150 plus an additional incentive). To be eligible to participate in the November contest, artists must stream their first event by Monday, November 8. Artists earn a cash prize with each stream during the month:

• Go Live 1X = $10
• Go Live 2X = $20
• Go Live 3X = $30
• Go Live 4X = $40
• Go Live 5X = $50

Altogether, these total the $150 cash prize for completing the streams during the month. Those artists who promote all five of their streams on Instagram and tag @fanpasslive earn an additional $25, bringing the earnings potential to $175. The Fan Pass platform also released its first-ever fall merchandise line in late October (https://ibn.fm/cplJ6). The new line is available for a limited time and features ten new products and over 20 new colors. Product pricing begins at $25 and up, offering shirts, hats, hoodies, and more. For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com. NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL

• The Cannabis World Congress & Business Exposition (CWCBExpo) will be held in New York between November 4-6, 2021
• The conference will feature over 50 expert speakers, in addition to hundreds of exhibitors showcasing the sector’s latest product innovations
• Recent forecasts have estimated overall US marijuana retail sales to rise from $20 billion in 2020 to $38.4-45.9 billion by 2025

The Cannabis World Congress & Business Exposition (“CWCBExpo”) event is set to be held at New York City’s Javits Convention Center, Hall 3A between 4-6 November 2021. Set to be held during Cannabis Week, a weeklong event taking place between Monday November 1 – Sunday November 7, the CWCBExpo is a business-to-business trade show event dedicated to the legalized cannabis industry. The CWCBExpo has rapidly earnt a reputation as a leading forum for dispensary owners, growers, suppliers, investors, medical professionals, government regulators, legal counsel, and entrepreneurs looking to achieve business success and identify new areas of growth in this dynamic and fast-growing industry. Following a big 2020, during which cannabis sales increased by 48 percent, or $6.9 billion, the highest dollar increase in U.S. industry history, 2021 has thus far benefitted from strong sales momentum across a number of states. Mature markets such as Colorado, Oregon and Washington state have averaged 26% year-over-year growth over the first half of this year; meanwhile, states which have recently decriminalized cannabis usage, such as Illinois, Massachusetts, Michigan and Pennsylvania are witnessing sales growth of upwards of 136% – albeit, from a low base (https://ibn.fm/hegWP). With seven states set to potentially pursue legislation in the coming years which will legalize the recreational use of cannabis – including the likes of Ohio, Missouri, South Dakota, Oklahoma, North Dakota, Maryland and Arkansas, the upcoming CWCBExpo will seek to harness on the recent growth trends through a series of presentations, keynote addresses and case studies spanning a wide array of topics. The conference will be segmented into three daily themes – covering ‘Where We Are Today’, ‘Challenges & Solutions’ and ‘What’s Next?’, respectively. Topics which will be covered include:

• Industry Update: Data, Highlights, Trends and Opportunities
• New York: From Illicit into the Light
• International Cannabis: Delivering the Infrastructure to Enable Worldwide Markets
• Opportunities at the Intersection of Hemp and Marijuana

A full list of the presentation topics to be covered over the three-day event can be found at: https://s23.a2zinc.net/clients/leexpos/cwcbexpony2021/Public/Sessions.aspx?View=Sessions_summary&ID=723 In addition to the conference’s wide array of expert speakers and industry thought leaders, the summit will also play host to hundreds of exhibitors set to feature some of the industry’s latest innovations, products, and services. Attendees will also be able to participate in an industry networking event, “Back-to-Business Celebration”, which will be held immediately post the first day of the CWCBExpo, wherein conference delegates will be able to network and further their interactions with their fellow peers. For more information about the CWCBExpo, visit https://cwcbexpo.com/